Our studies have shown that anergy, which is expressed by inhibition through the interaction of CTLA-4 and CD86, is an important mechanism leading to the inhibition of the antitumor response and CLL progression. The gene discussed is CTLA4; the disease is B-cell chronic lymphocytic leukemia.